drugset / Trial / NCT07743138

STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)

NCT07743138 ↗

Phase 2 Not yet recruiting 20 enrolled M.D. Anderson Cancer Center Summit Therapeutics · collab
RandomizedSingle-groupOpen-labelTreatment

Summary

To learn if ivonescimab can help to control previously treated, locally advanced or metastatic ACC or PPGL.

Timeline

Start
2027-02-07
Primary completion
2028-05-01
Completion
2030-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivonescimab Monoclonal antibody — Intravenous